Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology
|
April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
American Journal of Hematology
|
September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
Alex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances
|
February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML
Nicholas J Short, Naval Daver, Courtney D Dinardo, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia
|
August 14, 2025
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax
Jennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Blood Cancer Journal
|
March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology
|
April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
American Journal of Hematology
|
September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
Alex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances
|
February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML
Nicholas J Short, Naval Daver, Courtney D Dinardo, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia
|
August 14, 2025
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax
Jennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Blood Cancer Journal
|
March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Page
of 5